Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3915-23. doi: 10.1158/0008-5472.CAN-08-0206.

2.

The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.

Quatromoni JG, Suzuki E, Okusanya O, Judy BF, Bhojnagarwala P, Venegas O, Eruslanov E, Predina JD, Albelda SM, Singhal S.

BMC Immunol. 2013 Jul 17;14:30. doi: 10.1186/1471-2172-14-30.

3.

Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, Berzofsky JA.

Int J Cancer. 2010 Apr 1;126(7):1666-74. doi: 10.1002/ijc.24961.

4.

Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment.

Nie W, Yu T, Sang Y, Gao X.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):1400-1406. doi: 10.1016/j.bbrc.2016.12.048. Epub 2016 Dec 10.

PMID:
27956175
6.

TGF-β cytokine signaling promotes CD8+ T cell development and low-affinity CD4+ T cell homeostasis by regulation of interleukin-7 receptor α expression.

Ouyang W, Oh SA, Ma Q, Bivona MR, Zhu J, Li MO.

Immunity. 2013 Aug 22;39(2):335-46. doi: 10.1016/j.immuni.2013.07.016. Epub 2013 Aug 8.

7.

Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.

Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C.

Prostate. 2006 Feb 15;66(3):235-47.

PMID:
16173028
8.
9.

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C.

Mol Cancer Ther. 2006 Jul;5(7):1733-43.

10.

Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity.

Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath MG.

Diabetes. 2008 Oct;57(10):2684-92. doi: 10.2337/db08-0609. Epub 2008 Aug 8.

11.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

12.
13.

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.

Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM.

Clin Cancer Res. 2004 Sep 1;10(17):5907-18.

14.

Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes.

Papadakis KA, Krempski J, Reiter J, Svingen P, Xiong Y, Sarmento OF, Huseby A, Johnson AJ, Lomberk GA, Urrutia RA, Faubion WA.

Am J Physiol Cell Physiol. 2015 Mar 1;308(5):C362-71. doi: 10.1152/ajpcell.00262.2014. Epub 2014 Dec 3.

15.

Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K.

J Immunother. 2010 Apr;33(3):236-49. doi: 10.1097/CJI.0b013e3181c0c1cb.

PMID:
20445344
16.

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3835-43. doi: 10.1158/0008-5472.CAN-08-0215.

17.

Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation.

Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA.

Cancer Immunol Immunother. 2008 Jun;57(6):907-12. Epub 2007 Nov 15.

PMID:
18004566
18.

Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.

Lucas PJ, Kim SJ, Mackall CL, Telford WG, Chu YW, Hakim FT, Gress RE.

Blood. 2006 Oct 15;108(8):2789-95. Epub 2006 Jun 20.

19.
20.

Immune compartmentalization of T cell subsets in chemically-induced breast cancer.

Fahmi T, Esendagli G, Yilmaz G, Kansu E, Guc D.

Scand J Immunol. 2010 Oct;72(4):339-48. doi: 10.1111/j.1365-3083.2010.02447.x.

Supplemental Content

Support Center